Curia

Various factors must be considered when it comes to developing and delivering high-quality pharmaceutical drug products or medical devices to end users. A CDMO can help ensure products maintain quality standards and are readily available as necessitated throughout development, manufacturing, and commercialization.

Responding to the development of more novel therapies and fast-track designations means being equipped with the right processes and resources to support expedited approvals right from the beginning of process development.

You have your drug substance and need a parenteral formulation to administer it. This podcast will focus on the key factors to consider when choosing the ideal parenteral manufacturing CDMO partner.

Antibodies and proteins are critical reagents with wide application in in vitro diagnostic developments, companion diagnostic and biomarker assays. Depending on final application, different quality standards may apply, from research use to full GMP production. Learn more about Curia’s GMP Production of antibodies & proteins for critical assays and diagnostic applications.

The clinical value of biologics for the treatment of many disease indications has been accompanied by phenomenal sales. By 2026, the global market for biologics is projected to increase to $537 billion. However, getting a promising drug candidate from formulation development to clinical phase production and commercial manufacturing can be daunting. Proper formulation development has a huge impact on whether a technology transfer to clinical phase fill-finish is successful. Learn more!

Protein engineering has greatly benefited by the advent of in vitro display platforms, where individual or large libraries of peptides or proteins are displayed on the surface of mammalian, yeast, or bacterial cells or even bacteriophage capsids. Learn more about the main principles of phage and yeast surface display platforms & how Curia can power your antibody discovery and engineering projects.

Learn how CDMOs have integrated and delivered innovation to advance customers from curiosity to cure.

Thursday, September 30, 2021 at 11am EDT| 8am PDT| 4pm BST| 5pm CEST In-vitro biochemical assays make the high-throughput screening of large compound libraries possible; however, without a strong hit-to-lead process, time and money are often wasted seeking out the most promising starting points. Register for this webinar to learn best practices for triaging hits and focusing efforts.